INDVIndivior Pharmaceuticals, Inc.
Is the price fair?
Cheap vs its sector. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What INDV's price assumes
Indivior Pharmaceuticals, Inc. trades at 12.3× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · cheaper than the typical name in its group
- Price / sales
- 3.05
Price / sales · today's price, trailing year to Jun 30, 2026
- EV / sales
- 3.25
EV / sales
Details›
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 10.3
- EV / salestoday's price, trailing year to Jun 30, 2026
- 3.25
- Healthcare median P/E503 names
- 27.9
- Drug Manufacturers - Specialty & Generic median P/E44 names
- 21.0
- Market capitalisation118.0 million shares, counted Jul 28, 2026
- $4.07B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, Specialty & Generic
Ranks #1 of 39 by RyuScore